• Technology and Data
  • Front End Sales and Marketing
  • Allergy
  • HIV
  • Women's Health
  • Migraine
  • Compounding
  • Continuous Glucose Monitoring
  • Mental Health Awareness
  • Veterinary Pharmacy
  • CBD
  • Infectious Disease
  • Eye Health
  • Digestive Health
  • Biosimilars
  • Influenza
  • Shingles
  • COPD Management
  • Pediatrics
  • Generics
  • Pain Management
  • COVID-19
  • Immunization
  • Oncology
  • Anticoagulants
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Respiratory
  • Heart Health
  • Cardiovascular Clinical Consult

Dr. Reddy’s launches moxifloxacin HCl

Article

Dr. Reddy’s Laboratories has launched moxifloxacin HCl tablets, 400 mg, a therapeutic equivalent generic version of Avelox on March 4, following FDA approval.

 

Dr. Reddy’s Laboratories has launched moxifloxacin HCl tablets, 400 mg, a therapeutic equivalent generic version of Avelox on March 4, following FDA approval.

This fluoroquinolone is indicated for the treatment of adults with community-acquired pneumonia, acute exacerbations of chronic bronchitis, acute bacterial sinusitis, complicated skin and skin structure infections, pelvic inflammatory disease, and complicated intra-abdominal infections.

The product carries a warning that fluoroquinolones are associated with an increased risk of tendinitis and tendon rupture for patients of any age. There is a further increased risk in patients over 60 years of age, those taking corticosteroids, and individuals with kidney, heart, or lung transplants. Fluoroquinolones should not be used in patients with a history of myasthenia gravis as the drugs may exacerbate muscle weakness.

The brand name product had $195 million in U.S. sales for 2013, according to IMS Health.

Dr. Reddy’s generic moxifloxacin tablets, 400 mg, is available in bottle counts of 30.

Related Videos
fake news misinformation | Image Credit: Bits and Splits - stock.adobe.com
Dr. Charles Lee
© 2023 MJH Life Sciences

All rights reserved.